KNSA Earnings & Financial Statements
Kiniksa Pharmaceuticals, Ltd.
$78.84
+$0.31(+0.39%)
61
Overall
40
Value
63
Tech
81
Quality
Market Cap
$6.15B
Volume
576.51K
52W Range
$35.20 - $82.94
Target Price
$96.11
KNSA earnings and financial statements: Kiniksa Pharmaceuticals, Ltd.'s income statement, balance sheet and cash flow statement, annual and quarterly.
KNSA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $677.56M | $423.24M | $270.26M | $220.18M | $38.54M |
| Cost of revenue | $307.22M | $60.91M | $33.41M | $22.89M | $9.10M |
| Operating income | $77.22M | -$45.62M | -$25.20M | $9.77M | -$156.64M |
| EBITDA | $90.42M | -$34.46M | -$14.31M | $11.03M | -$154.28M |
| Net income | $59.01M | -$43.19M | $14.08M | $183.36M | -$157.92M |
| EPS (diluted) | $0.75 | $-0.60 | $0.20 | $2.60 | $-2.30 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $763.63M | $580.55M | $526.32M | $459.67M | $232.80M |
| Total liabilities | $196.03M | $142.12M | $87.48M | $63.52M | $47.76M |
| Shareholders’ equity | $567.61M | $438.44M | $438.84M | $396.15M | $185.04M |
| Cash and equivalents | $165.60M | $183.58M | $107.95M | $122.72M | $122.47M |
| Long-term debt | $6.51M | $7.86M | $10.01M | $2.62M | $2.67M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $137.99M | $25.69M | $13.30M | $5.81M | -$126.30M |
| Capital expenditure | -$1.57M | -$252.0K | -$130.0K | -$105.0K | -$20.41M |
| Free cash flow | $136.42M | $25.41M | $13.17M | $5.70M | -$146.71M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | KNSA | $78.84 | +0.4% | 576.51K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Kiniksa Pharmaceuticals, Ltd. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW